Overview
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
Status:
Recruiting
Recruiting
Trial end date:
2023-06-01
2023-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy of tradipitant in the treatment of motion sickness.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Vanda Pharmaceuticals
Criteria
Inclusion Criteria:- History of motion sickness
- Age 18-75
Exclusion Criteria:
- Nausea-inducing disorder other than motion sickness
- BMI>40
- History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists